JP2018513167A - 4−フェニル酪酸誘導体 - Google Patents
4−フェニル酪酸誘導体 Download PDFInfo
- Publication number
- JP2018513167A JP2018513167A JP2017554521A JP2017554521A JP2018513167A JP 2018513167 A JP2018513167 A JP 2018513167A JP 2017554521 A JP2017554521 A JP 2017554521A JP 2017554521 A JP2017554521 A JP 2017554521A JP 2018513167 A JP2018513167 A JP 2018513167A
- Authority
- JP
- Japan
- Prior art keywords
- phenylbutyric acid
- treatment
- acid derivative
- phenylbutyric
- derivative according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical class OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 238000011282 treatment Methods 0.000 claims abstract description 40
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims abstract description 22
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229950009215 phenylbutanoic acid Drugs 0.000 claims abstract description 15
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 11
- 229940024606 amino acid Drugs 0.000 claims abstract description 11
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 11
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 206010033103 otosclerosis Diseases 0.000 claims abstract description 6
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 5
- 208000019553 vascular disease Diseases 0.000 claims abstract description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 9
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 9
- 206010046996 Varicose vein Diseases 0.000 claims description 8
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 8
- 208000027185 varicose disease Diseases 0.000 claims description 8
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 7
- 208000024714 major depressive disease Diseases 0.000 claims description 7
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- 206010059245 Angiopathy Diseases 0.000 claims description 4
- 208000010484 vulvovaginitis Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 210000000013 bile duct Anatomy 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- VPZRWNZGLKXFOE-UHFFFAOYSA-M sodium phenylbutyrate Chemical compound [Na+].[O-]C(=O)CCCC1=CC=CC=C1 VPZRWNZGLKXFOE-UHFFFAOYSA-M 0.000 description 18
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010011878 Deafness Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 231100000888 hearing loss Toxicity 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XTXUHFXTTDVCNZ-SNVBAGLBSA-N (2r)-2-(4-phenylbutanoylamino)propanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)CCCC1=CC=CC=C1 XTXUHFXTTDVCNZ-SNVBAGLBSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000017283 Bile Duct disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000013707 sensory perception of sound Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
静脈瘤は、広げられ、ねじれた静脈である。静脈瘤はどこにでも起こり得るが、本用語は、一般に、足の静脈を意味する。静脈は、血液が逆流することを防ぐために、弁尖の対を有する。下肢筋は、重力の影響に逆らって血液を心臓に戻すために、静脈を圧縮する。静脈が静脈瘤になるとき、弁尖はもはや適切に合わず、弁は機能しない。これは血液が逆流することを可能にし、静脈はさらに広がる。静脈瘤は、足の表在静脈に最も多く、立っているときに高い圧力を受ける。美容上の問題であることと並んで、静脈瘤は特に立っているとき痛いことがある。過酷な長年の静脈瘤は、下肢の腫れ、静脈湿疹、皮膚の肥厚および潰瘍の原因となり得る。
本発明は、式1の4−フェニル酪酸誘導体に言及する。
本発明は、式1の4−フェニル酪酸誘導体を有する薬または調合薬にも関する。薬または調合薬は、人間および/または動物、好ましくは幼児、子供および大人を含む人間に対する用途のために好適な任意の形態であり得る。
人間および動物のための日用量は、それぞれの種、または年齢、性別、体重または病気の程度などの他の要因にそれらの根拠を有する要因により変化し得る。人間のための日用量は、活性化物質(式1の4−フェニル酪酸誘導体)の10mg〜2,000mgの範囲であり、一日あたり1回または複数回の摂取の間に投与される。好ましくは、人間のための日用量は、活性化物質(式1の4−フェニル酪酸誘導体)の100mg〜500mgの範囲であり、一日あたり1回または複数回の摂取の間に投与される。さらにより好ましくは、人間のための日用量は、活性化物質(式1の4−フェニル酪酸誘導体)の300mg〜400mgの範囲であり、一日あたり2回の摂取で投与される。
潰瘍性大腸炎の再発症を有する女性患者は、4−PBに対する良好な反応を示した。治療の6か月後、腸は正常であり、彼女にはもう痛みおよび下痢はなかった。
原発性硬化性胆管炎を有する2名の女性患者は、4−PBで治療された。両者は、数日間、再発性の熱および腹部の痛みを有した。両者は、肝臓移植のために選択された。4−PBを用いた治療の5か月後、両者には、症状および潜在的な胆管炎の兆候はなくなった。
コルチコイド軟膏を用いて数年間治療されていた一般的な乾癬を有する男性患者は、大腸癌のために4−PBを受容した。治療の4か月後、硬変は完全な鎮静を示した。4PBの期間の後も続いた。
2名の女性患者が他の理由のために(1名は癌のために、1名は鬱病のために)4−PBを用いて治療された。治療の4か月後、両者には外陰膣炎はなくなり、4−PBの期間の後でも完全に鎮静した状態にあった。
乳癌を持つ女性患者が4−PBを用いて治療された。癌のための療法の間、両足に拡大された静脈の消失が次の10年間、再発なく実現された。両足のクモ状静脈は変化しないままであった。
大鬱病性障害を持つ、何名かは他の疾患を患う、4名の女性患者および1名の男性患者が、4−PBを用いて治療された。驚くべきことに、鬱症状は3〜4か月の間消失した。再発は観察されていない。
10年以上の間続く耳鳴りを持つ2名の男性患者が、4−PBを用いて治療された。4か月の治療の後、両者の場合で、耳鳴りは消失した。
Claims (21)
- 式1の4−フェニル酪酸誘導体であって、
R1は、NH2またはHから選択され、
R2は、アミノ酸、サリチル酸、4−フェニル酪酸、カテコール、または前述されたいずれかの誘導体のラジカルであり、
nは、0,1,2,3,4,5,6,7,8,9,または10から選択され、
炎症性疾患の治療における使用のための、4−フェニル酪酸誘導体。 - 炎症性大腸炎の治療における使用のための、請求項1に記載の4−フェニル酪酸誘導体。
- クローン病の治療における使用のための、請求項2に記載の4−フェニル酪酸誘導体。
- 潰瘍性大腸炎の治療における使用のための、請求項2に記載の4−フェニル酪酸誘導体。
- 胆管の炎症性疾患の治療における使用のための、請求項1に記載の4−フェニル酪酸誘導体。
- 原発性硬化性胆管炎の治療における使用のための、請求項5に記載の4−フェニル酪酸誘導体。
- 炎症性皮膚疾患の治療における使用のための、請求項1に記載の4−フェニル酪酸誘導体。
- 乾癬の治療における使用のための、請求項7に記載の4−フェニル酪酸誘導体。
- 再発性外陰膣炎の治療における使用のための、請求項1に記載の4−フェニル酪酸誘導体。
- 式1の4−フェニル酪酸誘導体であって、
R1は、NH2またはHから選択され、
R2は、アミノ酸、サリチル酸、4−フェニル酪酸、カテコール、または前述されたいずれかの誘導体のラジカルであり、
nは、0,1,2,3,4,5,6,7,8,9,または10から選択され、
血管障害性疾患の治療における使用のための、4−フェニル酪酸誘導体。 - 静脈瘤の治療における使用のための、請求項10に記載の4−フェニル酪酸誘導体。
- 動脈硬化症の治療における使用のための、請求項10に記載の4−フェニル酪酸誘導体。
- 式1の4−フェニル酪酸誘導体であって、
R1は、NH2またはHから選択され、
R2は、アミノ酸、サリチル酸、4−フェニル酪酸、カテコール、または前述されたいずれかの誘導体のラジカルであり、
nは、0,1,2,3,4,5,6,7,8,9,または10から選択され、
耳硬化症の治療における使用のための、4−フェニル酪酸誘導体。 - 式1の4−フェニル酪酸誘導体であって、
R1は、NH2またはHから選択され、
R2は、アミノ酸、サリチル酸、4−フェニル酪酸、カテコール、または前述されたいずれかの誘導体のラジカルであり、
nは、0,1,2,3,4,5,6,7,8,9,または10から選択され、
精神疾患の治療における使用のための、4−フェニル酪酸誘導体。 - 大鬱病性障害の治療における使用のための、請求項14に記載の4−フェニル酪酸誘導体。
- 式1の4−フェニル酪酸誘導体であって、
R1は、NH2またはHから選択され、
R2は、アミノ酸、サリチル酸、4−フェニル酪酸、カテコール、または前述されたいずれかの誘導体のラジカルであり、
nは、0,1,2,3,4,5,6,7,8,9,または10から選択され、
耳鳴りの治療における使用のための、4−フェニル酪酸誘導体。 - R2は、以下の構造のいずれかから選択され、
- Yは、H2であり、
R2は、
R3は、Hまたは以下の構造のいずれかから選択される、請求項1〜16のうちの1項に記載の4−フェニル酪酸誘導体。
- R2は、以下の構造のいずれかから選択される、請求項1〜16のうちの1項に記載の4−フェニル酪酸誘導体。
- 以下の構造のいずれかから選択される、請求項17に記載の4−フェニル酪酸誘導体。
- 以下の構造のいずれかから選択される、請求項19に記載の4−フェニル酪酸誘導体。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/058329 WO2016165770A1 (en) | 2015-04-16 | 2015-04-16 | 4-phenylbutyric acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018513167A true JP2018513167A (ja) | 2018-05-24 |
JP6609322B2 JP6609322B2 (ja) | 2019-11-20 |
Family
ID=52875703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554521A Active JP6609322B2 (ja) | 2015-04-16 | 2015-04-16 | 4−フェニル酪酸誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180085333A1 (ja) |
EP (1) | EP3283066B1 (ja) |
JP (1) | JP6609322B2 (ja) |
DK (1) | DK3283066T3 (ja) |
WO (1) | WO2016165770A1 (ja) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58189121A (ja) * | 1982-04-30 | 1983-11-04 | Ajinomoto Co Inc | インシユリン投与賦活剤 |
JPS63104981A (ja) * | 1986-10-17 | 1988-05-10 | イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド | 7−オキサビシクロヘプタン置換ヒドロキサム酸プロスタグランジン類縁体 |
JP2004509941A (ja) * | 2000-09-29 | 2004-04-02 | プロリフィクス リミテッド | Hdacインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US20070066646A1 (en) * | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
EP2599767A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | Phenylbutyl-derivatives |
JP5544357B2 (ja) * | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
WO2014198372A1 (de) * | 2013-06-12 | 2014-12-18 | Merck Patent Gmbh | Hydroxyethylenderivate zur behandlung von arthrose |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2389932A1 (en) * | 2010-05-28 | 2011-11-30 | Lunamed AG | Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts |
-
2015
- 2015-04-16 US US15/563,202 patent/US20180085333A1/en not_active Abandoned
- 2015-04-16 EP EP15716808.9A patent/EP3283066B1/en active Active
- 2015-04-16 JP JP2017554521A patent/JP6609322B2/ja active Active
- 2015-04-16 DK DK15716808.9T patent/DK3283066T3/da active
- 2015-04-16 WO PCT/EP2015/058329 patent/WO2016165770A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58189121A (ja) * | 1982-04-30 | 1983-11-04 | Ajinomoto Co Inc | インシユリン投与賦活剤 |
JPS63104981A (ja) * | 1986-10-17 | 1988-05-10 | イー・アール・スクイブ・アンド・サンズ・インコーポレイテッド | 7−オキサビシクロヘプタン置換ヒドロキサム酸プロスタグランジン類縁体 |
JP2004509941A (ja) * | 2000-09-29 | 2004-04-02 | プロリフィクス リミテッド | Hdacインヒビターとしてのアミド結合を含むカルバミン酸化合物 |
US20040229948A1 (en) * | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
US20070066646A1 (en) * | 2005-08-02 | 2007-03-22 | Genmedica Therapeutics Sl | Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof |
JP5544357B2 (ja) * | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
EP2599767A1 (en) * | 2011-11-30 | 2013-06-05 | Lunamed AG | Phenylbutyl-derivatives |
WO2014198372A1 (de) * | 2013-06-12 | 2014-12-18 | Merck Patent Gmbh | Hydroxyethylenderivate zur behandlung von arthrose |
Non-Patent Citations (6)
Title |
---|
COMTE,B. ET AL.: "Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans", JOURNAL OF MASS SPECTROMETRY, vol. 37, no. 6, JPN6018047845, 2002, pages 581 - 590, ISSN: 0004041970 * |
FLORANCE,J. ET AL.: "Chiral high-performance liquid chromatography of aromatic cyclic dipeptides using cyclodextrin stati", JOURNAL OF CHROMATOGRAPHY, vol. 543, no. 2, JPN6018047847, 1991, pages 299 - 305, XP026514951, ISSN: 0004041972, DOI: 10.1016/S0021-9673(01)95782-6 * |
IWAMURA,T. ET AL., GIFU YAKKA DAIGAKU KIYO, vol. 46, JPN7018004108, 1997, pages 37 - 46, ISSN: 0004041974 * |
SAITO,M. ET AL.: "Synthesis and inhibitory activity of acyl-peptidyl-pyrrolidine derivatives toward post-proline cleav", JOURNAL OF ENZYME INHIBITION, vol. 5, no. 1, JPN6018047846, 1991, pages 51 - 75, XP000197459, ISSN: 0004041971 * |
SATTENAPALLY,N. ET AL.: "N-Butyl-2,4-dinitro-anilinium p-toluenesulfonate as a highly active and selective esterification cat", TETRAHEDRON LETTERS, vol. 54, no. 48, JPN6018047848, 2013, pages 6665 - 6668, ISSN: 0004041973 * |
WANG,C. ET AL., YAOWU SHIPIN FENXI, vol. 18, no. 6, JPN6018047844, 2010, pages 371 - 379, ISSN: 0004041969 * |
Also Published As
Publication number | Publication date |
---|---|
EP3283066A1 (en) | 2018-02-21 |
DK3283066T3 (da) | 2022-08-08 |
JP6609322B2 (ja) | 2019-11-20 |
EP3283066B1 (en) | 2022-05-11 |
WO2016165770A1 (en) | 2016-10-20 |
US20180085333A1 (en) | 2018-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180033517A (ko) | 홍합 접착 단백질 제품, 및 점막 염증을 억제하기 위한 그것의 용도 | |
KR20080108999A (ko) | 염증성 장질환 치료제 | |
JP2021502392A5 (ja) | ||
TWI324589B (en) | Halogenated bioactive lipid compound | |
TW201827044A (zh) | 用於治療發炎性腸病的組合物 | |
JP6609322B2 (ja) | 4−フェニル酪酸誘導体 | |
KR101320945B1 (ko) | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 | |
JP7411875B2 (ja) | ベータ-ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物 | |
TW201601715A (zh) | 膀胱‧尿道協同失調改善劑 | |
TW200927092A (en) | New medical use of 3-(2,2,2-trimethylhydrazinium) propionate salts | |
RU2632443C1 (ru) | Способ лечения билиарного сладжа у больных хроническим билиарнозависимым панкреатитом | |
KR101758949B1 (ko) | 활성 성분으로 l-카르니틴 또는 프로피오닐 l-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물 | |
KR100793236B1 (ko) | 대장염 치료용 약학적 조성물 | |
JP2013087108A (ja) | 炎症性腸疾患の予防または治療剤 | |
US11717013B1 (en) | Micronutrient combination to reduce blood pressure | |
US20200138776A1 (en) | Composition for use in the treatment of endometriosis and symptoms associated with endometriosis | |
JP2013234136A (ja) | リンパ浮腫治療薬及び治療方法 | |
US20090209503A1 (en) | Colonic delivery therapeutic agents for inflammatory bowel disease | |
WO2019169712A1 (zh) | 丁酸类化合物在促进组织内源性干细胞活化、增殖和分化中的应用 | |
JP2007084514A (ja) | 炎症性腸疾患用グリチルリチン製剤 | |
WO2024035859A1 (en) | Combination therapies for treating inflammation | |
AU757114B2 (en) | Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis | |
WO2022162633A1 (en) | Micronutrient composition and method to reduce high blood pressure | |
JP2006045200A (ja) | 間質性膀胱炎の治療薬 | |
SU1264947A1 (ru) | Способ лечени неспецифического звенного колита с тотальным поражением толстой кишки |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180402 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190301 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190827 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6609322 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |